Translational Nuclear Receptor Research Lab, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Front Immunol. 2019 Aug 9;10:1769. doi: 10.3389/fimmu.2019.01769. eCollection 2019.
Glucocorticoids (GCs) act via the glucocorticoid receptor (NR3C1, GRα) to combat overshooting responses to infectious stimuli, including lipopolysaccharide (LPS). As such, GCs inhibit the activity of downstream effector cytokines, such as tumor necrosis factor (TNF). PPARα (NR1C1) is a nuclear receptor described to function on the crossroad between lipid metabolism and control of inflammation. In the current work, we have investigated the molecular mechanism by which GCs and PPARα agonists cooperate to jointly inhibit NF-κB-driven expression in A549 cells. We discovered a nuclear mechanism that predominantly targets Mitogen- and Stress-activated protein Kinase-1 activation upon co-triggering GRα and PPARα. GST-pull down data further support that the anti-inflammatory mechanism may additionally involve a non-competitive physical interaction between the p65 subunit of NF-κB, GRα, and PPARα. Finally, to study metabolic effector target cells common to both receptors, we overlaid the effect of GRα and PPARα crosstalk in mouse primary hepatocytes under LPS-induced inflammatory conditions on a genome-wide level. RNA-seq results revealed lipid metabolism genes that were upregulated and inflammatory genes that were additively downregulated. Validation at the cytokine protein level finally supported a consistent additive anti-inflammatory response in hepatocytes.
糖皮质激素(GCs)通过糖皮质激素受体(NR3C1,GRα)发挥作用,以对抗包括脂多糖(LPS)在内的感染性刺激物的过度反应。因此,GCs 抑制下游效应细胞因子(如肿瘤坏死因子(TNF))的活性。过氧化物酶体增殖物激活受体α(PPARα,NR1C1)是一种核受体,被描述为在脂质代谢和炎症控制的交汇点发挥作用。在目前的工作中,我们研究了 GCs 和 PPARα 激动剂共同抑制 A549 细胞中 NF-κB 驱动的表达的分子机制。我们发现了一种主要针对 GRα 和 PPARα 共同触发时丝裂原和应激激活蛋白激酶-1 激活的核机制。GST 下拉数据进一步支持抗炎机制可能还涉及 NF-κB 的 p65 亚基、GRα 和 PPARα 之间的非竞争性物理相互作用。最后,为了研究两个受体共有的代谢效应靶细胞,我们在 LPS 诱导的炎症条件下,在小鼠原代肝细胞中,在全基因组水平上叠加了 GRα 和 PPARα 串扰的影响。RNA-seq 结果显示脂质代谢基因上调,炎症基因下调。细胞因子蛋白水平的验证最终支持了肝细胞中一致的附加抗炎反应。